Gilead Sciences (GILD) Announces China National Medical Products Administration Approves Biktarvy for Treatment of HIV-1 Infection

August 9, 2019 8:32 AM
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy® (bictegravir 50mg/emtricitabine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles